NASDAQ

Erasca, Inc. (ERAS)

547 Thanks from members

Erasca, Inc. (ERAS) exhibits a high-beta, polarized market narrative driven by encouraging Phase 1 data for ERAS-0015, a fortified balance sheet with ~$384 million in cash, and aggressive equity raises, balanced against widening net losses, securities class-action litigation, and patent infringement allegations.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →